Pipeline
Development and Commercialization of Prescription Medication for People with Paroxysmal Supraventricular Tachycardia (PSVT) and Under Clinical Investigation for Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
We are preparing to advance etripamil into a Phase 3 program in atrial fibrillation with rapid ventricular rate (AFib-RVR), following a successful Phase 2 trial. We are also actively recruiting in a Phase 2 study exploring the potential of etripamil as a treatment for the pediatric population with PSVT.
If you have questions, please contact us.
Etripamil is currently under clinical investigation for the acute treatment of patients with fast heart rates associated with AFib.
If you are interested in participating in a clinical trial, please contact your healthcare provider.
Milestone Pharmaceuticals does not currently have an expanded access policy.
For information regarding access to Milestone’s clinical trials, please visit clinicaltrials.gov.
.png){kind=small}